A high-entropy nanozyme-based photothermal-adjuvant <i>in situ</i> nanovaccine for potentiated tumor immunotherapy
A qPBA nanocube-based HEzyme as a photothermal-adjuvant ICD-driven in situ nanovaccine was developed for potentiated tumor immunotherapy via ROS amplification and TAM repolarization.
Authors
- Kui Luo (ORCID: https://orcid.org/0000-0002-3536-1485)
- Yixin Xing (ORCID: https://orcid.org/0000-0001-5888-9648)
- Yuying Yin (ORCID: https://orcid.org/0000-0002-5287-4311)
- Peng Zhao (ORCID: https://orcid.org/0000-0002-5479-899X)
- Chenlu Yin
- Wei Gu (ORCID: https://orcid.org/0000-0001-5908-1616)
- Jingqiang Xue
Institutions
- Capital Medical University (CN)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
Publication Details
- Journal
- Materials Chemistry Frontiers
- Published
- 2025-01-01
- DOI
- https://doi.org/10.1039/d5qm00334b
- Citations
- 1
- Primary Topic
- Nanoplatforms for cancer theranostics
- Type
- article
- Field-Weighted Citation Impact
- 0.67
Funders
- Beijing Municipal Commission of Education
- Natural Science Foundation of Beijing Municipality